SACI-IO HR+: Ana Garrido-Castro MD | Dana-Farber Cancer Institute
Follow
Antibodydrug conjugate plus a checkpoint inhibitor shows a trend toward improved survival in PDL1positive hormone receptorpositive, HER2negative breast cancer. DanaFarber's Ana GarridoCastro, MD, presented findings at #ASCO24. Video published 6/7/2024